IL7R and neoplasm: However, their therapeutic efficacy is often limited by poor persistence and activity within the tumor microenvironment (TME) caused by a lack of essential cytokines.<h4>Methods</h4>To overcome cytokine dependence, we engineered NK92, primary NK (pNK), and chimeric antigen receptor (CAR)-NK92 cells to express an interleukin-7 receptor with an insertion mutation (IL-7R-IM), which induces constitutive signaling.